Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Consensus Rating of "Buy" from Brokerages

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) have received an average rating of "Buy" from the eight brokerages that are presently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $27.71.

CNTA has been the topic of a number of research analyst reports. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a "buy" rating on the stock. Piper Sandler initiated coverage on shares of Centessa Pharmaceuticals in a research note on Monday, March 31st. They set an "overweight" rating and a $38.00 price objective for the company. Guggenheim reissued a "buy" rating and issued a $28.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Finally, Morgan Stanley reiterated an "overweight" rating and issued a $27.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th.

Centessa Pharmaceuticals Stock Up 0.6 %

NASDAQ:CNTA traded up $0.07 during mid-day trading on Friday, hitting $12.08. The stock had a trading volume of 495,060 shares, compared to its average volume of 620,963. The company has a market capitalization of $1.61 billion, a PE ratio of -7.90 and a beta of 1.53. The stock has a 50-day simple moving average of $14.00 and a two-hundred day simple moving average of $15.72. Centessa Pharmaceuticals has a twelve month low of $7.75 and a twelve month high of $19.09. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.38) by $0.04. On average, equities research analysts anticipate that Centessa Pharmaceuticals will post -1.6 EPS for the current year.

Insider Transactions at Centessa Pharmaceuticals

In related news, General Counsel Iqbal J. Hussain sold 2,080 shares of the business's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $14.01, for a total transaction of $29,140.80. Following the transaction, the general counsel now directly owns 105,386 shares of the company's stock, valued at approximately $1,476,457.86. The trade was a 1.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Karen M. Anderson sold 30,526 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $19.03, for a total transaction of $580,909.78. Following the completion of the sale, the insider now owns 54,322 shares of the company's stock, valued at approximately $1,033,747.66. The trade was a 35.98 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 202,353 shares of company stock valued at $3,286,478 over the last ninety days. Corporate insiders own 11.59% of the company's stock.

Institutional Trading of Centessa Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of CNTA. State Street Corp purchased a new position in Centessa Pharmaceuticals in the third quarter valued at about $777,000. Geode Capital Management LLC grew its stake in shares of Centessa Pharmaceuticals by 68.7% in the 3rd quarter. Geode Capital Management LLC now owns 56,597 shares of the company's stock valued at $905,000 after buying an additional 23,058 shares in the last quarter. Franklin Resources Inc. increased its holdings in Centessa Pharmaceuticals by 99.1% in the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company's stock worth $38,360,000 after buying an additional 1,145,823 shares during the last quarter. Lord Abbett & CO. LLC bought a new position in Centessa Pharmaceuticals during the third quarter valued at approximately $4,305,000. Finally, JPMorgan Chase & Co. raised its position in Centessa Pharmaceuticals by 1,969.2% during the third quarter. JPMorgan Chase & Co. now owns 135,903 shares of the company's stock valued at $2,173,000 after acquiring an additional 129,335 shares in the last quarter. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.